0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TIM-3

TIM-3

TIM-3 Molecule Information

Name:Hepatitis A virus cellular receptor 2
Target Synonym:TIM-3;T-cell immunoglobulin and mucin domain-containing protein 3;TIMD3;HAVcr-2;TIMD-3;T-cell membrane protein 3;T-cell immunoglobulin mucin receptor 3;TIM3;HAVCR2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Phase ?

TIM-3 Protein Product ListCompare or Buy

TIM-3 Molecule Synonym Name

HAVCR2,TIM3,TIMD3,FLJ14428,KIM3

TIM-3 Molecule Background

Hepatitis A virus cellular receptor 2 is also known as HAVCR2, FLJ14428,  KIM3, TIM3, TIMD3, is a member of the TIM family of immune regulating molecules with one Ig-like V-type domain and a Ser/Thr-rich mucin stalk. CD4-positive T helper lymphocytes can be divided into types 1 (Th1) and 2 (Th2) on the basis of their cytokine secretion patterns. Th1 cells and their associated cytokines are involved in cell-mediated immunity to intracellular pathogens and delayed-type hypersensitivity reactions, whereas Th2 cells are involved in the control of extracellular helminthic infections and the promotion of atopic and allergic diseases. The 2 types of cells also cross-regulate the functions of the other. HAVCR2 is a Th1-specific cell surface protein that regulates macrophage activation and enhances the severity of experimental autoimmune encephalomyelitis in mice. HAVCR2 regulates macrophage activation. Inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance. May be also involved in T-cell homing. Dysregulation of the HAVCR2-galectin-9 pathway could underlie chronic autoimmune disease states in human, such as multiple sclerosis.

TIM-3 References

TIM-3 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
INCAGN-02390 INCAGN-02390 Phase Ⅰ Agenus, Incyte Cancer Details
BMS-986258 BMS-986258; ONO-7807 Phase Ⅱ Bristol-Myers Squibb, Five Prime Therapeutics, Ono Pharmaceutical Solid tumours Details
Cobolimab TSR-022 Phase Ⅱ AnaptysBio, Tesaro, GlaxoSmithKline Solid tumours Details
CA-327 CA-327; AUPM-327 Preclinical Aurigene, Curis Cancer Details
LY-3321367 LY-3321367 Phase Ⅰ Lilly Solid tumours Details
BGB-A425 BGB-A425 Phase Ⅱ BeiGene Cancer Details
RO-7121661 RG-7769; RO-7121661 Phase Ⅱ Roche Non small cell lung cancer (NSCLC), Solid tumours, Melanoma Details
MBG-453 MBG-453 Phase Ⅱ Novartis Myelodysplastic syndrome (MDS) Details
Sym-023 Sym-023 Phase Ⅰ Symphogen Solid tumours, Lymphoma Details
LY-3415244 LY-3415244 Phase Ⅰ Lilly Solid tumours Details
SHR-1702 SHR-1702,SHR1702 Phase Ⅰ Shanghai Hengrui, Jiangsu Hengrui Medicine Solid tumours Details

This web search service is supported by Google Inc.

totop